Computational Biophysical Chemistry

Computational Biophysical Chemistry

Wael Rabeh Photo

Wael Rabeh

Associate Professor of Biochemistry
Affiliation: New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
Education:
* Ph.D., Biochemistry, University of Oklahoma, Norman, OK, USA
* M.S., Biochemistry, University of Oklahoma, Norman, OK, USA
* B.S., Biological Chemistry, University of Damascus, Syria
Email: Send Email
Curriculum Vitae: Download
Website: Structural Biology and Biophysical Chemistry (SBBC) laboratory

Academic Biography

Professor Wael Rabeh received his PhD in 2004 at the Biochemistry Department, University of Oklahoma, where he carried the mechanistic characterization of the last enzyme in the cysteine biosynthetic pathway in Salmonella typhimurium.

In 2005, Prof. Rabeh joined the Structural Genomic Consortium (SGC) at the University of Toronto as a postdoctoral fellow, where he characterized the 3D structure of human proteins with medical relevance using X-ray crystallography.

To further expand his expertise in the field of protein chemistry, in 2007, Prof. Rabeh joined the lab of Prof. Gergely Lukacs at McGill University in Montreal Canada for the characterization of a membrane channel that is the main cause of Cystic Fibrosis.

In 2010, Prof. Rabeh joined the faculty of chemistry at New York University Abu Dhabi to establish the chemistry and biochemistry teaching and research programs.

Research Interest

Research Areas:

  • Enzymology
  • Protein Structures
  • Cancer Metabolism
  • Bioluminescence
  • SARS-CoV-2

Professor Wael Rabeh’s research interests lie at the intersection of biochemistry, structural biology, and therapeutic discovery, with a strong focus on understanding protein mechanisms and their implications in human health. His work spans diverse areas, including cancer metabolism, bioluminescence, and antiviral strategies against SARS-CoV-2, reflecting his commitment to addressing pressing biomedical challenges.

One of Prof. Rabeh’s primary research areas is the characterization of disease-causing protein mechanisms to facilitate the discovery and design of novel therapeutics. His work on human Hexokinase 2, a protein essential for tumor initiation and growth, exemplifies his focus on cancer metabolism. Cancer cells exhibit significantly elevated glucose consumption compared to normal tissues, a feature critical for their rapid proliferation. Professor Rabeh’s research aims to target glucose metabolism selectively in cancer cells, providing a promising pathway for developing safer and more effective anticancer treatments with minimal side effects.

In the field of bioluminescence, Prof. Rabeh’s laboratory investigates the molecular basis of light emission in fireflies and other bioluminescent species. By studying luciferase enzymes, his team seeks to unravel the mechanisms driving the production of different colors of light from the same chemical reaction. This work has broad implications for applications such as in vivo imaging, cell proliferation monitoring, protein folding studies, and environmental and food quality assessments. Understanding these mechanisms not only sheds light on a fascinating natural phenomenon but also advances technologies in diverse scientific domains.

Professor Rabeh’s research also extends to combating global health crises, as demonstrated by his work on SARS-CoV-2. His lab focuses on the biochemical and biophysical characterization of the virus’s main proteases, 3CLpro and PLpro, which are essential for viral replication. By targeting these proteases, his team aims to develop antiviral therapeutics that can effectively inhibit the progression of COVID-19, contributing to global efforts to control the pandemic.

Through his multifaceted research, Prof. Rabeh combines structural insights with biochemical expertise to address complex biological questions, driving innovations in therapeutic development and expanding our understanding of protein function in health and disease.

Publications

Peer-Reviewed Articles

  1. Ferreira, J.C.; Fadl, S.; Cardoso, T. H.S.; Andrade, B.S.; Melo, T.S.; Andrade Silva, E.M.; Agarwal, A.; Turville, S.J.; Saksena, N. K.; Rabeh, W.M. Boosting immunity: synergistic antiviral effects of luteolin, vitamin C, magnesium and zinc against SARS-CoV-2 3CLpro. Biosci Rep (2024) 44 (8): BSR20240617. https://doi.org/10.1042/BSR20240617

  2. Ferreira, J.C.; Villanueva, A.J.; Fadl, S.; Al Adem, K.; Cinviz, Z.N.; Nedyalkova, L.; Cardoso, T. H.S.; Andrade, M.E.; Saksena, Sensoy, O.; Rabeh, W.M. Residues in the Fructose Binding Pocket Are Required for Ketohexokinase-A Activity. J. Biol. Chem. (2024):107538. https://doi.org/10.1016/j.jbc.2024.107538

  3. Al Adem, K.; Ferreira, J.C.; Villanueva, A.J.; Fadl, S.; El-Sadaany, F.; Masmoudi, I.; Gidiya, Y.; Gurudza, T.; Cardoso, T. H.S.; Saksena, N. K.; Rabeh, W.M. 3-chymotrypsin-like protease in SARS-CoV-2. Bioscience Reports. (2024) 44 (8): BSR20231395 (Invited review paper). https://doi.org/10.1042/BSR20231395

  4. Mahgoub, R.E.; Mohamed, F.; Alzyoud, L.; Ali, B.R.; Ferreira, J.C.; Rabeh, W.M.; AlNeyadi, S.S.; Atatreh, N.; Ghattas, M.A. Discovery of Pyrimidoindol and Benzylpyrrolyl Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro) through Pharmacophore Modelling, Covalent Docking, and Biological Evaluation. J. Mol. Graph. Model. (2023) 108672. https://doi.org/10.1016/j.jmgm.2023.108672

  5. Alzyoud, L.; Mahgoub, R.E.; Mohamed, F.; Ali, B.R.; Ferreira, J.C.; Rabeh, W.M.; Atatreh, N.; Ghattas, M.A. The Discovery of Novel Small Oxindole-based Inhibitors Targeting the SARS-CoV-2 Main Protease (Mpro). Chemistry & Biodiversity (2023) e202301176. https://doi.org/10.1002/cbdv.202301176

  6. Saksena, N. K.; Reddy, S. B.; Saksena, M. M.; Cardoso, T. H.S.; Silva, E. M.A.; Ferreira, J.C.; Rabeh, W.M. SARS-CoV-2 variants, its recombinants and epigenomic exploitation of host defenses. BBA Molecular Basis of Disease (2023) 1869(8):166836. https://doi.org/10.1016/j.bbadis.2023.166836

  7. Al Adem, K.; Ferreira, J.C.; Fadl, S.; Rabeh, W.M. Key Allosteric and Active Site Residues of SARS-CoV-2 3CLpro Are Promising Drug Targets. Biochem. J. (2023) 480 (11):791–813. https://doi.org/10.1042/bcj20230027

  8. Al Adem, K.; Ferreira, J.C.; Fadl, S.; Rabeh, W.M. pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity. J. Biol. Chem. (2023) 299 (2):102790. https://doi.org/10.1016/j.jbc.2022.102790

  9. Mahgoub, R.E.; Mohamed, F.; Alzyoud, L.; Ali, B.R.; Ferreira, J.C.; Rabeh, W.M.; AlNeyadi, S.S.; Atatreh, N.; Ghattas, M.A. The Discovery of Small Leadlike Inhibitors of the SARS-Cov-2 Main Protease via Structure-Based Virtual Screening and Biological Evaluation. Molecules (2022) 27(19):6710. https://doi.org/10.3390/molecules27196710

  10. Shetler, C.L.; Ferreira, J.C.; Cardoso, T.H.S.; Silva, E.M.A.; Saksena, N.K.; Rabeh, W.M. Therapeutic potential of metal ions for COVID-19: insights from the papain-like protease of SARS-CoV-2. Biochme. J. (2022); BCJ20220380. https://doi.org/10.1042/bcj20220380

  11. Yozgat, Y.; Karakoc, E.; Sahin, O.; Cimen, S.; Rabeh, W.M.; Aydin, M.S.; Mardinoglu, A.; Gursel, I.; Cakir, A.; Sensoy, O. Ozdemir, E.M.; Bayrak, Y.; Gunluoglu, M.Z.; Saatci, O.; Jabbar, J.; Ferreira, J.C.; Aslan, M.D.; Yildirim, M.; Mansoor, S.; Kerman, B.E.; Aladag, Z.; Kim, W.; Arif, M.; Vatandaslar, E.; Tok, O.E.; Dogru, Z.; Demir, A.G.O.; Yildirim, T.C.; Yozgat, I.; Senturk, S.; Ozturk, G.; Cevher, M.A. Hexokinase 1b is a novel target for Non–small-cell lung cancer. bioRxiv. https://doi.org/10.1101/2022.06.27.497447

  12. Ferreira, J.C.; Fadl, S.; Rabeh, W.M. Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2. J. Biol. Chem. (2022) 298(6):102023. https://doi.org/10.1016/j.jbc.2022.102023

  13. Ferreira, J.C.; Fadl, S.; Ilter, M.; Pekel, H.; Rezgui, R.; Sensoy, O.; Rabeh, W.M. Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS-CoV-2 protease 3CLpro. FASEB J. (2021) https://doi.org/10.1096/fj.202100994

  14. Ferreira, J.C.; Fadl, S.; Villanueva, A.J.; Rabeh, W.M. Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-like Protease. Front. Chem. (2021). https://doi.org/10.3389/fchem.2021.692168

  15. Ferreira, J.C.; Abdul-Rahman Khrbtli, A.R.; Shetler, C.L.; Mansoor, S.; Ali, L.; Sensoy, O.; Rabeh, W.M. Linker residues regulate the activity and stability of hexokinase 2, a promising anticancer target. J. Biol. Chem. (2021) 296:100071. https://doi.org/10.1074/jbc.ra120.015293

  16. Ferreira, J.C.; Rabeh, W.M. Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2. Scientific Reports (2020) v.10:22200. https://doi.org/10.1038/s41598-020-79357-0

  17. López, C.C.; Ferreira, J.C.; Lui, N.M.; Schramm, S.; Berraud-Pache, R.; Navizet, I.; Panjikar, S.; Naumov, P.; Rabeh, W.M. Beetle luciferases with naturally red- and blue-shifted emissions. Life Science Alliance. (2018) 1(4) e201800072. https://doi.org/10.26508/lsa.201800072

  18. Whelan, J.; Koussa, J.; Chehade, I.; Sabanovic; M.; Chang, A.; Carelli, D.; An, Z.; Zhang, L.; Bernstein, J.; Rabeh, W.M. Crystal Growth, a Research‐Driven Laboratory Course. J. Appl. Cryst. (2018). 51, 1474–1480. https://doi.org/10.1107/S1600576718009573

  19. Nawaz, M.H.*; Ferreira, J.C.; Nedyalkova, L.; Zhu, H.Z.; López, C.C.; Kirmizialtin, S.; Rabeh, W.M.* The Catalytic Inactivation of the N-half of Human Hexokinase 2 and Structural and Biochemical Characterization of its Mitochondrial Interactions. Bioscience Reports. (2018) 38(1). BSR20171666. *Co-first Authors. https://doi.org/10.1042/bsr20171666

  20. Vunnam, S.; Mazitschek, R.; Kariem, N.M.; Reddy, A.; Rabeh, W.; Li, L.; O’Connor, M.J.; Al-Tel, T.H. Modular Bi-Directional One-Pot Strategies for the Diastereoselective Synthesis of Structurally Diverse Collections of Constrained β-Carboline-Benzoxazepines. Chem. Eur. J. (2017). https://doi.org/10.1002/chem.201702495

  21. Woldetsadik, A.D.; Vogel, M.C.; Rabeh, W.M.; Magzoub, M. Hexokinase II-derived cell-penetrating peptide targets mitochondria and triggers apoptosis in cancer cells. FASEB J. (2017) 31(5):2168-2184. https://doi.org/10.1096/fj.201601173r

  22. Gražulis, S.; Sarjeant, A.A.; Moeck, P.; Stone-Sundberg, J.; Snyder, T.J.; Kaminsky, W.; Oliver, A.G.; Stern, C.L.; Dawe, L.N.; Rychkov, D.A.; Losev, E.A.; Boldyreva, E.V.; Tanski, J.M.; Bernstein, J.; Rabeh, W.M.; Kantardjieff, K.A. Crystallographic education in the 21st century. J. Appl. Cryst. (2015) 48: 1964-1975. https://doi.org/10.1107/s1600576715016830

  23. Nath, N.K.; Yasuda, N.; Rabeh, W.M.; Chandra Sahoo, S.; Naumov, P. Structural Elucidation of the Neuraminidase Inhibitor Zanamivir (Relenza): Creeping and Diffusion for Polymorph Separation. Cryst. Growth Des. (2014) 14 (2): 770–774. https://doi.org/10.1021/cg4016383

  24. Naumov P.; Yasuda, N.; Rabeh W.M.; Bernstein, J. The elusive crystal structure of the neuraminidase inhibitor Tamiflu (oseltamivir phosphate): molecular details of action. Chem Commun. (2013) 49:1948-50. https://doi.org/10.1039/c3cc38801h

  25. Ahner, A.; Gong, X.; Schmidt, BZ.; Peters, K.W.; Rabeh, W.M.; Thibodeau, P.H.; Lukacs, G.L.; Frizzell, R.A. Small heat shock proteins target mutant CFTR for degradation via a SUMO-dependent pathway. Mol. Biol. Cell (2013) 24(2):74-84. https://doi.org/10.1091/mbc.e12-09-0678

  26. Rabeh, W.M.; Bossard, F.; Xu, H.; Okiyoneda, T.; Bagdany, M.; Liu, Y.; Mulvihill, C.M.; Du, K.; Di Bernardo, S.; Konermann, L.; Roldan, A.; Lukacs, G.L. Correction of both NBD1 energetics and domain interface is required to restore ∆F508 CFTR folding and function. Cell; (2012) 148(1-2): 150-63. (Featured on the cover page of Science-Business eXchange). https://doi.org/10.1016/j.cell.2011.11.024

  27. Colas, J.; Faure, G.; Saussereau, E.; Trudel, S.; Rabeh, W.M.; Bitam, S.; Guerrera, I.C.; Fritsch, J.; Sermet-Gaudelus, I.; Davezac, N.; Brouillard, F.; Lukacs, G.L.; Herrmann, H.; Ollero, M. and Edelman, A. Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect. Hum. Mol. Genet. (2012) 21(3): 623-34. https://doi.org/10.1093/hmg/ddr496
  28. Wyatt, E.; Wu, R.; Rabeh, W.; Park, H.W.; Ghanefar, M. and Ardehali, H. Regulation and Cytoprotective Role of Hexokinase III. PLoS One. (2010) 5(11): e13823. https://doi.org/10.1371/journal.pone.0013823

  29. Okiyoneda, T.; Barrière, H.; Bagdány, M.; Rabeh, W.M.; Du, K.; Höhfeld, J.; Young, J.C. and Lukacs, G.L. Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane. Science. (2010) 805-10. https://doi.org/10.1126/science.1191542

  30. Tai, C.H., Rabeh, W.M., Guan, R., Schnackerz, K.D. and Cook, P.F. Role of Histidine-152 in cofactor orientation in the PLP-dependent O-acetylserine sulfhydrylase reaction. Arch. Biochem. Biophys. (2008) 472, 115-25. https://doi.org/10.1016/j.abb.2008.01.021

  31. Tai, C.H., Rabeh, W.M., Guan, R., Schnackerz, K.D. and Cook, P.F. Effect of mutation of lysine-120, located at the entry to the active site of O-acetylserine sulfhydrylase-A from Salmonella typhimurium. Biochim. Biophys. Acta. (2008) 1784, 629-37. https://doi.org/10.1016/j.bbapap.2007.12.017
  32. Tempel, W.*, Rabeh, W.M.*, Bogan, K.L., Belenky, P., Wojcik, M., Seidle, H.F., Nedyalkova, L., Yang, T., Sauve,A.A., Park, H.W. and Brenner,C. Nicotinamide Riboside Kinase Structures Reveal New Pathways to NAD+. PLoS Biol. (2007) 5(10): e263 *Co-first Authors. https://doi.org/10.1371/journal.pbio.0050263
  33. Hong, B.S., Senisterra, G., Rabeh, W.M., Vedadi, M., Leonardi, R., Zhang, Y.M., Rock, C.O., Jackowski, S. and Park, H.W. Crystal Structures of Human Pantothenate Kinases: Insights into Allosteric Regulation and Mutations linked to Neurodegeneration Disorder. J. Bio. Chem. (2007) 282, 27984-93. https://doi.org/10.1074/jbc.m701915200
  34. Dong A, Xu X, Edwards AM, Chang C, Chruszcz M, Cuff M, …. eta…Rabeh W, Shen L, Shen Y, Sukumard D, Tempel W, Tong Y, Tresagues L, Vedadi M, Walker JR, Weigelt J, Welin M, Wu H, Xiao T, Zeng H, Zhu H. In situ proteolysis for protein crystallization and structure determination. Nat. Methods. (2007) 4, 1019-21. https://doi.org/10.1038/nmeth1118
  35. Chattopadhyay, A.*, Meier, M., Ivaninskii, S., Burkhard , P., Speroni, F.*, Campanini, B., Bettati, S., Mozzarelli, A., Rabeh, W.M.*, Li, L. and Cook, P.F. Structure, Mechanism, and Conformational Dynamics of O-Acetylserine Sulfhydrylase from Salmonella typhimurium: Comparison of A and B Isozymes. Biochemistry (2007) 46, 8315-30 *Co-first Authors. https://doi.org/10.1021/bi602603c
  36. Rabeh, W.M., Mather, T. and Cook, P. F. A Three-Dimensional Homology Model of the O-Acetylserine Sulfhydrylase-B from Salmonella typhimurium. Protein Pept Lett. (2006) 13, 7-13. https://doi.org/10.2174/092986606774502126
  37. Rabeh, W.M., Alguindigue, S. S. and Cook, P. F. Mechanism of the Addition Half of the O-Acetylserine Sulfhydrylase-A Reaction. Biochemistry (2005) 44, 5541-50. https://doi.org/10.1021/bi047479i
  38. Rabeh, W.M., and Cook, P. F. Structure and Mechanism of O-Acetylserine Sulfhydrylase. J. Bio. Chem. (2004) 279, 26803-26806. https://doi.org/10.1074/jbc.r400001200

Conferences, Symposiums, and Workshops: Invited Talks

  1. New Insights into Color Emission of Beetle Luciferases. June 3–7, 2024. 22nd International Symposium for Bioluminescence (ISBC), Foz do Iguacu, Brazil.

  2. New Insights in Cancer Inhibition and Therapeutics. Feb 5 – 7, 2024. The American Chemical Society (ACS) conference for the Middle East and Africa (MEA). Abu Dhabi, UAE. (Keynote Speaker)

  3. The proteases of SARS-CoV-2 for antiviral development. Oct 25 – 27, 2023. International Meeting of the Microbiological Society of Korea (MSK2023). Yeosu-si, South Korea.

  4. Drug Development Against COVID-19. Dec 5-6, 2022. First UAE Scientific Conference on Health and Medical Research. Dubai, UAE.

  5. Non-active Site Residues Inactivate the N-terminal Domain of the Human Hexokinase 2. Oct 30–Nov 2, 2022. The 17th conference of the Asian Crystallographic Association (AsCA2022). Jeju-do, South Korea.

  6. Protein Crystal Growth in Microgravity for Anticancer Drug Discovery. Oct 20, 2022. Space Life Sciences Workshop, Mohammed Bin Rashid Space Centre & Mohammed Bin Rashid University, Dubai, UAE.

  7. Dimer interface for the inhibition of Main Protease of SARS-CoV-2. June 21-23, 2022. 4th Protein Engineering Canada (PEC) Conference, Concordia University, Montreal, QC Canada.

  8. Protein Dynamics Insight into the Origin of the Green and Red Emission of Beetle Luciferases. May 31-Jun 3, 2022. 21 st International Symposium for Bioluminescence (ISBC), Gijon, Spain.

  9. Characterization of the 3CLpro main protease of SARS-CoV2. Mar. 09-10, 2021. Regional E-Gathering in Chemistry. Virtual conference.

  10. Glucose Metabolism for the Inhibition of Cancer Growth. Jan. 12-14, 2020. The 3rd NYU Biomedical and Biosystems Conference. NYUAD, Abu Dhabi, UAE.

  11. The American Chemical Society (ACS) Chapter in the UAE. Oct. 26-31, 2019. Arab Chemistry Week. University of Sharjah, Sharjah, UAE.

  12. The Color Tuning Mechanism of Beetle Luciferases. Nov. 12-14, 2018. The 2nd Middle-Eastern Materials Science Conference. NYUAD, Abu Dhabi, UAE.

  13. The Color Emission of Beetle Luciferases. June 18, 2018. Protein Engineering Canada (PEC) Conference, the University of British Columbia, Vancouver, B.C. Canada.

  14. Cancer Metabolism and its Therapeutic Applications. Nov. 4, 2017. The 4th Middle East Molecular Biology (MEMBS) Congress and Exhibition. Abu Dhabi, UAE.

  15. The Catalytic and Structural Roles of the Human Hexokinase 2 in Cancer. March 21, 2017. 2nd International Conference on Enzymology and Molecular Biology. Rome, Italy.

  16. Glucose Metabolism in Cancer and its Therapeutic Applications. March 1, 2016. 2nd UAE Conference on Pure and Applied Chemistry (ECPAC16). American University of Sharjah, Sharjah, UAE.

  17. Glycolysis in Cancer Metabolism and Apoptosis. Feb. 16, 2016. 7th International Conference on Drug Discovery and Therapy. Eureka conference. University of Sharjah, Sharjah, UAE.

  18. The Warburg Effect and Molecular Mechanism of Human Hexokinase 2 in Cancer Metabolism and Apoptosis. Aug 17, 2015. Beatson Institute, Cancer Research UK, Glasgow, UK.

  19. Structural and Molecular Mechanisms of Human Hexokinase 2 in Cancer Metabolism and Apoptosis. Mar 18, 2015. Sharjah Institute for Medical Research (SIMR), the University of Sharjah. Sharjah, UAE.

  20. Human Hexokinase 2: a Key Enzyme and Promoter of Tumor Growth. Nov. 23-25, 2013. ARC’13: Qatar Foundation Annual Research Conference. Doha, Qatar.

  21. Glycolysis in Cancer Metabolism and Apoptosis. Feb. 16, 2016. 7th International Conference on Drug Discovery and Therapy. University of Sharjah, Sharjah, UAE.

  22. Glucose Metabolism in Cancer and its Therapeutic Applications. March 1, 2016. 2nd UAE Conference on Pure and Applied Chemistry (ECPAC16). American University of Sharjah, Sharjah, UAE.

  23. Cystic Fibrosis Disease Mechanism: Recovery of the Misfolded CFTR Channel. Jun. 3-6, 2013. Drug Discovery & Therapy World Congress. Boston, USA.

  24. Crystal Growth to Foster Inquiry−Based Learning: First Year Science Laboratory. Aug. 5-12, 2014. 23rd International Union of Crystallography (IUCr) Congress. Montreal, QC, Canada.

  25. Correction of the Misfolded Cystic Fibrosis Transmembrane Conductance Regulator Channel is a Two-Step Process. Feb. 18-21, 2013. 5th International Conference on Drug Discovery & Therapy. Dubai, UAE.

  26. Correction of Both NBD1 Energetics and Domain Interface is Required to Restore ΔF508 CFTR Folding and Function. Jun. 6-9, 2012. 35th European Cystic Fibrosis Conference. P.54. Dublin, Ireland.

  27. Conformational stabilization of the NBD1 is necessary, but not sufficient for CFTR biogenesis. Oct 21-23, 2010. The 24nd Annual North American Cystic Fibrosis Conference. Baltimore, MD, United States. Pediatric Pulmonology 2010. P.220

Conferences, Symposiums, and Workshops: Non-Invited Presentations

  1. César Carrasco-López, Juliana C. Ferreira, & Wael M. Rabeh. Beetle Luciferases and their Color Emission. 18-23 Aug 2019. 32nd European Crystallographic Meeting (ECM32). Vienna, Austria.

  2. Abdulrahman Khrbtli, Juliana C. Ferreira, César Carrasco-López, & Wael M. Rabeh. Red or Blue Emission of Beetle Luciferases and their Applications. 22-26 July 2019. 6th SSBSS in Pisa, Italy.

  3. César Carrasco-López, Juliana Ferreira, & Wael Rabeh. The Origin of Color Emission of Beetle Luciferases. Mar. 28-30, 2019. The 9th International Conference on Biomedical Engineering & Technology. Tokyo, Japan.

  4. Ferreira, J.; Nawaz, M.H.; Rabeh, W.M. Cancer Metabolism and the Human Hexokinase 2 as an Anticancer Target. 7-12 July 2018. The 43rd FEBS congress in Prague, Czech Republic.

  5. Ferreira, J.; Nawaz, M.H.; Rabeh, W.M. Characterization of the Human Hexokinase 2 role in Cancer Metabolism and Apoptosis. July 16-21, 2017. Enzymes, Coenzymes & Metabolic Pathways; a Gordon Research Conference (GRC) in Waterville Valley, NH, USA.

  6. Nawaz, M.H.; Rabeh, W.M. Human Hexokinase 2 in Cancer Metabolism and Apoptosis. Sep. 28-30, 2015. Cancer and Metabolism conference, an Abcam cancer conference series. Robinson College, Cambridge, UK.

  7. Nawaz, M.H.; Rabeh, W.M. Mechanisms of Action of the Human Hexokinase 2 in Cancer Metabolism and Apoptosis. Aug. 19-21, 2015. Carbohydrate Active Enzymes in Medicine and Biotechnology. University of St Andrews, St Andrews, Scotland.

  8. Nawaz, M.H.; Rabeh, W.M.; Structural and Molecular Mechanisms of Human Hexokinase 2 in Cancer Metabolism and Apoptosis. Metabolism and Cancer; an American Association for Cancer Research (AACR) special conference. June 7 – 10, 2015; Bellevue, Washington, USA.

  9. Nawaz, M.H.; Rabeh, W.M.; How to Cure Cancer with a Pill? A Structure-Based Drug Design Study on Human Hexokinase 2 targeting different Tumor types. ARC’14: Qatar Foundation Annual Research Conference. Nov. 18-19, 2014. Doha, Qatar.

  10. Nawaz, M.H.; Rabeh, W.M. The Mitochondrial Dissociation Effect on the Human Hexokinase 2 and its role in Tumor Progression. Enzyme mechanisms by biological systems, EMBO conference. Jun. 1-4, 2014. Manchester, UK.

  11. Rabeh, W.M.; Bossard,F.; Xu, H.; Okiyoneda, T.; Bagdany, M.; Mulvihill, C.M.; Du, K.;Di Bernardo, S.; Liu, Y.; Konermann, L.; Roldan, A. and Lukacs, G.L. Recovery of the Genetic Mutation of CFTR Channel and the Cystic Fibrosis Disease Mechanism. ARC’13: Qatar Foundation Annual Research Conference. Nov. 23-25, 2013. Doha, Qatar.

  12. Okiyoneda, T.; Guido, V.; Xu, H.; Roldan, A.; Bagdany, M.; Rabeh, W.M.; Lukacs, G.L. Pharmaco- and chemical-chaperone combination synergistically rescues the delF508-CFTR coupled domain-folding defect in cystic fibrosis. Molecular Chaperones & Stress Responses. May 1- 5, 2012. Cold Spring Harbor, NY, USA.

  13. Rabeh, W.M. Protein Science in drug discovery and design. 1st Material Science Symposium: Mar. 8, 2012, Abu Dhabi, the United Arab Emirates (Oral presentation).

  14. Rabeh, W.M., Bossard, F., Di Bernardo, S., Okiyoneda, T., Liu, Y., Mulvihill, C.M., Du, K., Xu, H., Konermann, L., Lukacs, G.L. Linking the deletion of F508 imposed localized NBD1 folding defect to CFTR cooperative misassembly in cystic fibrosis. 1st Arab-American Frontiers Symposium: Oct. 17-19, 2011, Kuwait City, Kuwait.

  15. Rabeh, W.M.; Zhu, H.; Nedyalkova, L.; Tempel, W.; Vedadi, M.; Arrowsmith, C.H. and Edwards, A.M. The Crystal Structure of Human Hexokinase 2: a Key Enzyme and Promoter of Tumor Growth. Changing Landscape of the Cancer Genome: June 20 – 25, 2011, Boston, MA, USA.

  16. Rabeh, W.M. et al. (2010) Conformational stabilization of the NBD1 is necessary, but not sufficient for CFTR biogenesis. Ped. Pulm. Suppl. 33, 220

  17. Okiyoneda, T. ; Apaja, P.M.; Barriere, H.; Bagdany, M.; Rabeh, W.M.; Du, K.; Hohfeld, J.; Young, J.C.; Lukacs, G.L. Protein quality control mechanism responsible for triage decision of unfolded CFTR at plasma membrane. Gordon Research Conference (Lysosomes & endocytosis): Jun 20-25, 2010. Andover, NH, USA.

  18. Gong, X., Ahner, A., Schmidt, B., Rabeh, W.M, Lukacs, G., Thibodeau, P., Frizzell, R.A. Preferential Sumoylation of ∆F508 CFTR and NBD1 Leads to Protein Degradation. The 33rd European Cystic Fibrosis Society Conference: Jun 16-19, 2010, Valencia, Spain.

  19. Rabeh, W.M., Di Bernardo, S., Xu, H., Mulvihill, C.M., Du, K. and Lukacs, G.L. CFTR Folding in Vitro and in Vivo: Implication of Cooperative Domain Assembly. 2010 ECFS Basic Science Conference: April 7-10, 2010, Carcavelos, Portugal. European Cystic Fibrosis Society

  20. Okiyoneda, T. ; Barriere, H.; Bagdany, M.; Rabeh, W.M.; Young, J.C.; Lukacs, G.L. Quality control machinery responsible for ubiquitination and elimination of misfolded CFTR from the cell surface. Annual GRASP/MSBR Symposium: Nov 23-24, 2009, Montreal, QC, Canada.

  21. Okiyoneda, T. ; Barriere, H.; Bagdany, M.; Rabeh, W.M.; Young, J.C.; Lukacs, G.L. Quality control machinery responsible for ubiquitination and elimination of misfolded CFTR from the cell surface. Cell Stress Society International (CSSI) The 4th International Congress on Stress Response in Biology and Medicine, The 4th Annual Meeting of The Biomedical Society for Stress Response (BSSR): Oct 6-9, 2009, Sapporo, Japan.

  22. Exploring protein-protein interaction via mass spectroscopy workshop: Jun 16, 2009, Life Sciences Complex. Montreal, Quebec, Canada. McGill University.

  23. Rabeh, W.M., Mulvihill, C.M., Di Bernardo, S.,Bagdany, M., Du, K. and Lukacs, G.L. The Biophysical Characteristics defect of ∆F508 on the nucleotide binding domain 1 of the cystic fibrosis transmembrane conductance regulator. The 1st Annual GRASP Symposium: Nov 24, 2008, Montreal, Quebec, Canada. Groupe de Recherche Axésur la Structure des Protéines.

  24. Rabeh, W.M., Mulvihill, C.M., Di Bernardo, S., Bagdany, M., Du, K. and Lukacs, G.L. Characterization of Wild-Type and ∆F508-NBD1 with a Single Solubilization Mutation. The 22 nd Annual North American Cystic Fibrosis Conference: Oct 23-25, 2008, Orlando, FL, United States. Pediatric Pulmonology 2008, p 205.

  25. Rabeh, W.M. and Cook, P.F. Mechanism of the second-half of the O-Acetylserine Sulfhydrylase-A reaction. The 19th Enzyme Mechanisms Conference: Jan 5-9, 2005 Pacific Grove, CA, United States.

  26. Rabeh, W.M. and Paul, F.C. Insights into the kinetic mechanism of Malic Enzyme from Ascaris suum. The 90th Annual Technical Meeting: Nov 2, 2001 Oklahoma City, OK, United States. Oklahoma Academy of Science.

Scroll to Top